For a period of 3 months the action of Bendigo on raised serum lipid levels was tested in 28 patients. Serum cholesterin dropped from 264 to 215 mg%, and triglycerides from 212 to 117 mg% - both changes being statistically significant. The change in the serum lipids may be ascribed to an inhibition of lipolysis, mainly induced by mesoinosit-hexonitolnicotinate. Hypertensive levels were significantly affected by Bendigon (drop from 210/101 to 165/76 mmHg). The combined action of the various drugs in Bendigon improves results of therapy with a low dosis, making long-term treatment without complications possible. This is of great importance in view of the significance of high serum lipid levels and hypertension as risk factors in the etiology of coronary heart disorders.